FDA Peptide Reclassification 2026: What It Means for Providers FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn FDA Peptide Regulation and HHS Policy Holt Law FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA's Overreach on Compounded Peptides The FDA's Ban of Therapeutic Peptides: A Threat to Health Freedom Slim 'n Sleek